Ocumetics Technology Corp (TSE:OTC)
:OTC
Want to see TSE:OTC full AI Analyst Report?
OTC Stock Chart & Stats
C$0.55
C$0.02(6.45%)
At close: 4:00 PM EST
C$0.55
C$0.02(6.45%)
Day’s Range― - ―
52-Week RangeC$0.35 - C$1.99
Previous CloseN/A
Volume36.17K
Average Volume (3M)77.99K
Market Cap
C$30.63M
Enterprise ValueC$33.68M
Total Cash (Recent Filing)C$436.82K
Total Debt (Recent Filing)C$5.70M
Price to Earnings (P/E)―
Beta0.58
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding57,789,104
10 Day Avg. Volume70,232
30 Day Avg. Volume77,988
Financial Highlights & Ratios
PEG Ratio-0.23
Price to Book (P/B)-18.65
Price to Sales (P/S)0.00
P/FCF Ratio-21.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Product Focus — Accommodating IOLA clear, specialized product focus on an accommodating IOL aligns the company with a defined commercial pathway in ophthalmic surgery. This concentrated R&D effort can produce durable IP and clinical differentiation if regulatory progress converts into marketable technology.
Progress Toward Regulatory ApprovalExplicit advancement toward regulatory approval and commercialization is a structural milestone: successful regulatory outcomes materially de-risk the business model, enable partner sales channels, and create a lasting pathway from R&D expense to recurring revenue.
Predictable Cash Burn DynamicsA near‑one-to-one relationship between net loss and free cash flow indicates predictable cash consumption tied to operating losses. That predictability supports more reliable financing plans, milestone budgeting, and clearer runway modeling for reaching commercialization.
Bears Say
No Revenue & Widening LossesAbsence of revenue and accelerating net losses are fundamental constraints: without product sales the company must rely on external funding, which increases dilution risk and limits ability to scale operations, invest in commercialization, or sustain multi‑period R&D without clear near‑term cash generation.
Deteriorated Balance Sheet & Rising DebtSharply higher debt and deeply negative equity materially weaken financial flexibility. Negative equity and limited asset base increase solvency risk, raise financing costs, and constrain the company's ability to withstand setbacks or pursue needed commercial scale‑up without onerous financing terms.
Sustained Negative Operating & Free Cash FlowPersistent operating and free cash‑flow deficits create ongoing funding pressure. Over the medium term this forces reliance on dilutive equity or debt financing, limits reinvestment capacity, and raises execution risk for clinical, regulatory, and commercial milestones needed to generate sustainable revenue.
Ocumetics Technology Corp News
OTC FAQ
What was Ocumetics Technology Corp’s price range in the past 12 months?
Ocumetics Technology Corp lowest stock price was C$0.35 and its highest was C$1.99 in the past 12 months.
What is Ocumetics Technology Corp’s market cap?
Ocumetics Technology Corp’s market cap is C$30.63M.
When is Ocumetics Technology Corp’s upcoming earnings report date?
Ocumetics Technology Corp’s upcoming earnings report date is Sep 01, 2026 which is in 82 days.
How were Ocumetics Technology Corp’s earnings last quarter?
Currently, no data Available
Is Ocumetics Technology Corp overvalued?
According to Wall Street analysts Ocumetics Technology Corp’s price is currently Overvalued.
Does Ocumetics Technology Corp pay dividends?
Ocumetics Technology Corp does not currently pay dividends.
What is Ocumetics Technology Corp’s EPS estimate?
Ocumetics Technology Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ocumetics Technology Corp have?
Ocumetics Technology Corp has 57,789,104 shares outstanding.
What happened to Ocumetics Technology Corp’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Ocumetics Technology Corp?
Currently, no hedge funds are holding shares in TSE:OTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ocumetics Technology Corp
Ocumetics Technology Corp. is an innovation-driven enterprise specializing in the development and production of diverse optical lenses. One of its key innovations is the Bionic Lens, an expandable intraocular lens crafted to be implanted within the eye's natural lens compartment, offering a solution that eliminates the need for external vision correction. The company maintains its corporate headquarters in Calgary, Canada.
Technical Analysis
Aurora Spine
―
Covalon Technologies
―
Perimeter Medical Imaging AI
―
VentriPoint Diagnostics
―
Conavi Medical
―
Options Prices
Currently, No data available
---